Last updated: 11/07/2018 11:59:45
HO-13-6591: Meta-Analysis Plan for 201151, GSK573719/GW642444, Further Validation of the Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease Using Data from DB2113361, DB2113373, DB2113360 and DB2113374.
GSK study ID
201151
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: HO-13-6591: Meta-Analysis Plan for 201151, GSK573719/GW642444, Further Validation of the Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease Using Data from DB2113361, DB2113373, DB2113360 and DB2113374.
Trial description: HO-13-6591: Meta-Analysis Plan for 201151, GSK573719/GW642444, Further Validation of the Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease Using Data from DB2113361, DB2113373, DB2113360 and DB2113374.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Maggie Tabberer, Jean Brooks and Teresa Wilcox. A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease. Health Qual Life Outcomes.2015;13(1):177.
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
umeclidinium bromide, umeclidinium bromide/vilanterol, vilanterol
Collaborators
Not applicable
Study date(s)
September 2013 to December 2013
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2013-24-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website